The firm is currently evaluating the safety and efficacy of AU-011, which is an injection to treat eye cancer, in the clinical trial phase 1b/2.
The data showed that multiple administrations of AU-011 to 46 patients were “well-tolerated” and caused adverse effects that were manageable with standard treatments.
Only one patient experienced vision loss, considered a severe adverse effect.
Treatment resulted in tumour control in 15 of the 17 patients who had tumour growth before enrolling in the trial, which is a 88% success rate.
“AU-011 is administered via a simple, two-step procedure which includes an intravitreal injection followed by a laser application; all of which is completed in the physician’s office,” said Jay S Duker, advisor at Aura.
“If approved, AU-011 represents the first potential new treatment for choroidal melanoma in several decades.”